An observational study in Muscular Dystrophy, Becker, Muscular Dystrophy and Muscular Dystrophy (DMD), sponsored by West China Second University Hospital. Not yet recruiting at 1 site in China. Open to male participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by West China Second University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Muscular Dystrophy, Duchenne with a site in China — 5 open to participants now, 10 under way, 1 of them phase 3. Muscular Dystrophy, Duchenne · China.
Among the 19 studies in Muscular Dystrophy, Duchenne with a site in China, this one is the only one that started in 2026, is one of 2 observational ones, and was the 19th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →5 of the 19 studies in Muscular Dystrophy, Duchenne with a site in China are open now. Recruiting first, the newest first:
Shanghai Siponuoyin Biotechnology Co Ltd · Sites in China
Ages 2–7 · Men only
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 4–8 · Men only
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 4–8 · Men only
Ning Wang, MD., PhD. · Sites in China
Ages 2+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 1 Year to 18 Years · male.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 6
First in 2011; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 60 across 132 observational studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 20 across the 17 interventional studies, 1,250 across the 2 observational. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 19 have an industry lead sponsor. The 10 most frequent:
West China Second University Hospital is the lead sponsor of 38 studies on the registry; 22 are open to participants now.
West China Second University Hospital has 1 study filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
1 of the studies in Muscular Dystrophy, Duchenne with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07282652Peking Union Medical College HospitalA Study to Evaluate the Safety and Tolerability of RAG-18 in Pediatric Patients With Duchenne Muscular Dystrophy | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Muscular Dystrophy, Duchenne with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, multicenter, longitudinal observational cohort study aimed at understanding the progression of Duchenne Muscular Dystrophy (DMD). The primary objective is to identify and integrate key biomarkers from multiple sources-including motor function assessments, body composition (muscle and fat distribution), clinical laboratory tests, and cardiopulmonary imaging-to delineate comprehensive disease trajectories. By analyzing how these factors change over time in a large cohort, the study seeks to develop a robust model that can identify patterns of disease progression. The ultimate goal is to generate evidence that may aid in forecasting individual patient outcomes and inform the future development of personalized rehabilitation and therapeutic strategies.
Detailed Description
Comprehensive Scientific Rationale and Knowledge Gap
Duchenne Muscular Dystrophy (DMD) is characterized by a highly heterogeneous disease trajectory that is not fully captured by single-domain assessments. While individual milestones of functional decline, such as loss of ambulation or decline in forced vital capacity, are well-established, the dynamic and complex interrelationships between skeletal muscle pathology, systemic fat metabolism, cardiopulmonary function, and real-world functional performance over time remain poorly quantified. This lack of a systems-level, integrated understanding of DMD progression fundamentally limits the ability of clinicians to prognosticate for individual patients, optimally time interventions, and proactively tailor rehabilitation and management plans.
Existing predictive models often rely on a limited set of functional or genetic parameters, failing to fully integrate the multi-systemic, physiological remodeling that occurs as the disease evolves. The central rationale for this study is that a more robust and clinically actionable understanding of progression can be achieved by synchronously capturing and integrating high-dimensional data across multiple physiological domains. Specifically, the detailed analysis of body composition-including the progressive atrophy of specific muscle groups, the patterns of ectopic fat infiltration within muscles and organs, and shifts in visceral adipose tissue distribution-is hypothesized to contain rich information reflective of the underlying molecular pathophysiology. We posit that the simultaneous longitudinal analysis of these compositional changes, in concert with traditional functional measures and advanced cardiopulmonary imaging, will reveal novel, synergistic biomarkers of disease progression that are not apparent when these domains are studied in isolation.
This study is designed to address a critical knowledge gap: the system-level mapping of how different organ systems deteriorate in relation to one another in DMD. The evidence base generated by this research is expected to be crucial for refining prognostic accuracy, informing the timely adjustment of rehabilitative strategies, and enabling sophisticated patient stratification for future clinical trials.
Overall Research Strategy and Multidimensional Data Integration Framework
The core innovation of this study lies not merely in the parallel collection of data, but in its sophisticated framework for integrating these multidimensional data streams to uncover their intrinsic relationships.
Longitudinal Synchronization of Data Acquisition: A foundational element of the study design is the concurrent collection of all data streams (functional, compositional, imaging, laboratory) at predefined intervals throughout the study duration. This temporal alignment is critical for establishing sequence and potential causality between variables. It enables the investigation of key questions, such as whether changes in body composition precede or simply coincide with measurable declines in motor function or cardiopulmonary performance.
Cross-Center Data Harmonization and Standardization: To ensure seamless data integration from multiple participating centers, the study will implement a comprehensive manual of standardized operating procedures (SOPs). These SOPs will govern every detail of all assessments and imaging protocols, encompassing patient preparation, device calibration, data acquisition, and post-processing pipelines. This rigorous quality control is a prerequisite for ensuring dataset integrity, minimizing inter-center variability, and guaranteeing that any observed differences in the final analysis reflect true biological heterogeneity rather than technical artifacts.
Advanced Analytics and Modeling Methodology:
Data Preprocessing and Feature Engineering: Raw data, particularly from imaging modalities, will be processed to extract quantitative, traceable features. Examples include deriving cross-sectional areas and fat fractions of specific muscle groups from magnetic resonance imaging (MRI), and calculating appendicular skeletal muscle index and fat mass index from body composition analysis.
Exploratory Analysis and Hypothesis Generation: The initial analytical phase will employ exploratory data analysis techniques, including principal component analysis and unsupervised clustering algorithms, to identify naturally occurring patient subgroups within the data without a priori assumptions. This approach has the potential to uncover novel DMD phenotypes based on patterns of progression.
Longitudinal Modeling: The core statistical analysis will utilize models specifically designed for repeated measures data. Mixed-effects models will be employed to quantify the intra- and inter-individual rates of change for each biomarker over time and to test associations between these rates of change and baseline covariates.
Integrated Model Development and Validation: In the final phase, machine learning algorithms will be used to develop a composite model that leverages all available multimodal data to most accurately characterize disease progression trajectories. Model performance will be rigorously assessed via internal validation techniques. The primary output will be a "Disease Progression Atlas" that maps the sequence and interrelationships of multi-system physiological decline, rather than a single, simplified prognostic score.
The ultimate output of this research is intended to be a data-driven, comprehensive atlas of DMD disease progression. This atlas will qualitatively and quantitatively describe how different physiological systems deteriorate in relation to one another, defining both common and divergent pathways of functional decline.
The anticipated findings and long-term impacts of this study include:
Deepening Pathophysiological Understanding: Elucidating the pathophysiological links between muscle composition, systemic metabolism, and functional capacity in DMD, with a specific focus on the role of ectopic fat infiltration in the progression of muscle weakness and the development of cardiopulmonary insufficiency.
Providing a Resource for Future Clinical Development: Establishing a foundational evidence base to support future clinical trials by enabling better patient stratification and identifying sensitive, multi-domain composite endpoints that may be more responsive to therapeutic interventions.
Advancing Precision Medicine: Informing the development of personalized management algorithms by clarifying which combinations of biomarkers are most informative for predicting outcomes at specific disease stages. For instance, determining whether the fat fraction of thigh muscles at a given clinical node is a more powerful predictor of ambulatory loss in the subsequent year than standard functional walk tests.
In summary, this study is designed to generate a foundational dataset that will serve as a critical resource for refining prognostic accuracy and accelerating the advancement of personalized therapeutic and rehabilitative strategies in DMD. By adopting this systematic, multimodal approach, we aim to move beyond traditional descriptive natural history studies and provide a new paradigm for understanding and managing this complex disease.
This is a multicenter observational natural history study of male children and adolescents with genetically confirmed Duchenne or Becker Muscular Dystrophy. Participants will be followed longitudinally to document the natural progression of muscle weakness, functional decline, and associated comorbidities. The study population includes individuals across a range of disease severity and ages, from early childhood to late adolescence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single cohort of children with Duchenne or Becker Muscular Dystrophy
Other: No interventions are applied; participants are followed for natural history observation only
This is an observational natural history study. No experimental interventions, treatments, or drugs are administered to participants. All data is collected through routine clinical care and follow-up assessments to document the natural progression of Duchenne and Becker Muscular Dystrophy.
NorthStar Ambulatory Assessment (NSAA) score
The NorthStar Ambulatory Assessment (NSAA) is a validated clinical scale to measure motor function in ambulatory boys with Duchenne or Becker Muscular Dystrophy.
Time frame: Baseline and 24 months
Start is estimated for Apr 2026; primary completion for Dec 2028, 32 months later.
Of 52 non-industry observational studies under Muscular Dystrophy, Duchenne, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 120. This study's planned 32 months is below that.
Counting every sponsor, half of 63 studies reached it within 40 months; a quarter within 12 and three quarters within 120.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophy, Duchenne →
West China Second University Hospital